We are live on !
Find out more
BCM
Biomark Capital Management Portfolio holdings
AUM
$8.9M
Turnover
0%
1-Year Est. Return
97.06%
This Fund
S&P 500
This Quarter Est. Return
+37.69%
1 Year Est. Return
+97.06%
3 Year Est. Return
+113.75%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$8.9M
AUM Growth
+$2.43M
(+38%)
Cap. Flow
$0
Cap. Flow % of AUM
Cap. Flow %
0%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
2
New
–
Increased
–
Reduced
–
Closed
–
Avg Time Held
2.4
years
Top 10 Avg Time Held
2.4
years
Top 20 Avg Time Held
2.4
years
Top Buys
No buys this quarter
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
ADMA Biologics
ADMA
$2.48B
| $8.9M | 99.96% |
1,433,304
| – | – |
2015 Q4
11 quarters
|
|
|
MBVX
2
DELISTED
MABVAX THERAPEUTICS HLDGS INC
MBVX
| $4K | 0.04% |
8,903
| – | – |
2016 Q3
8 quarters
|
|
Similar funds
OBP
HC
CIG
IPLA
GA
Biomark Capital Management's Q3 2018 Portfolio in Review
As of Q3 2018, Biomark Capital Management held 2 positions worth $8.9M, up 38% from $6.47M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Trading was light in Q3 2018: portfolio turnover was 0%. Biomark Capital Management opened no new positions and made no exits, leaving the 2-position portfolio largely intact.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- Biomark Capital Management's ten largest holdings make up 100% of its $8.9M portfolio in Q3 2018.
- Biomark Capital Management opened 0 new positions and closed 0 in Q3 2018.
- Biomark Capital Management's portfolio value rose 38% quarter-over-quarter to $8.9M.
Based on Biomark Capital Management's 13F filing for Q3 2018, filed 24 Oct 2018.